注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Zevra Therapeutics Inc (Zevra)(原名:KemPharm, Inc.)是一家罕见病公司。该公司致力于为治疗选择有限或没有治疗选择的疾病创造疗法。其产品包括Arimoclomol,这是一种口服给药的研究候选产品,用于治疗Neimann-Pick C型(NPC)。其KP1077是一种主要的临床候选药物,正在开发用于治疗特发性嗜睡症(IH)和发作性睡病。KP1077仅由哌甲酯(SDX)组成,这是Zevra的d-哌甲酯(d-MPH)前药。KP1077孤儿药用于治疗IH。该公司还提供AZSTARYS,这是一种前体药物,用于治疗6岁或以上患者的成人注意力缺陷/多动障碍(ADHD)。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Tamara A. Favorito | 64 | 2021 | Independent Chair |
Donald R. Jasinski | - | - | Member of Scientific and Medical Advisory Board |
Srinivas Nalamachu | - | 2013 | Co-Chair of Physician Advisory Council |
Douglas W. Calder | 57 | 2023 | Independent Director |
Thomas D. Anderson | 68 | 2023 | Independent Director |
Wendy L. Dixon | 69 | 2023 | Independent Director |
John B. Bode | - | 2023 | Independent Director |
Alvin Shih | 47 | 2024 | Independent Director |
Corey M. Watton | 54 | 2023 | Independent Director |
Robert Findling | - | - | Member of Scientific & Medical Advisory Board |
Barney Bishop | - | 2007 | Chairman of Scientific and Medical Advisory Board |
Jeffrey A. Gudin | 58 | 2013 | Co-Chair of Physician Advisory Council |
Neil F. McFarlane | 51 | 2023 | President, CEO & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核